Results 131 to 140 of about 4,504,355 (205)
Patient Journey, Disease Burden, Treatment Patterns, and the Impact of Delayed Diagnosis Among Patients With Sjögren's Disease: A Real‐World US Survey
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.Objective
The aim of this study was to investigate disease burden, treatment patterns, and impact of delayed diagnosis on patient outcomes in Sjögren's disease (SjD) in a real‐world setting in the United States. Methods
Data were drawn from the Adelphi Primary Sjögren's Syndrome Disease Specific Programme, a US‐based cross‐sectional collaborative ...Anjana Lalla, Antton Egana, Jack Milligan, Nicola Massey, James Haughton +4 morewiley +1 more sourceThe Impact of Caring for a Child With Juvenile Idiopathic Arthritis on Caregiver Quality of Life
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.Objective
Juvenile idiopathic arthritis (JIA) impacts children and their families, often increasing caregiver burden and diminishing quality of life. This study assessed the care‐related quality of life of parent‐caregivers of children with JIA using the Care‐Related Quality of Life instrument (CarerQol), identified the most affected caregiving ...Deborah A. Marshall, Ana Claudia Fuhrmann, Rodrigo Dal Ben, Gillian R. Currie, Rae S. M. Yeung, Sebastiaan J. Vastert, Nico Wulffraat, Joost F. Swart, Susanne Benseler, on behalf of the UCAN CAN‐DU and UCAN CURE Consortia, Rae Yeung, Shirley Tse, Deborah Levy, Ronald Laxer, Brian Feldman, Jennifer Ji Young Lee, Alisa Rachlis, Susanne Benseler, Nicole Johnson, Muhammed Dhalla, Paivi Miettunen, Heinrike Schmeling, Marinka Twilt, Rebeka Stevenson, Deborah Marshall, Andrea Human, David Cabral, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Tommy Gerschman, Herman Tam, Mercedes Chan, Ross Petty, Roman Jurencak, Nadia Luca, Ciarán Duffy, Tala El Tal, Roberta Berard, Jonathan Park, Erkan Demirkaya, Lily Lim, Adam Huber, Bianca Lang, Elizabeth Stringer, Chelsea DeCoste, Suzanne Ramsey, Dax G. Rumsey, Daniah Basodan, Lillian Lim, Hon Yan Ng, Jeanine McColl, Tara McGrath, Michelle Batthish, Tania Cellucci, Liane Heale, Claire LeBlanc, Gaëlle Chédeville, Rosie Scuccimarri, Sarah Campillo, Piya Lahiry, Paul Dancey, Nickolas Blanchette, Alan Rosenberg, Mehul Jariwala, Tristan Kerr, Kate Neufeld, Clare Hutchinson, Gordon Soon, Dieneke Schonenberg, Mariken Gruppen, Merlijn van den Berg, Giske Biesbroek, Philomine van Pelt, Marleen Verkaaik, Sylvia Kamphuis, Danielle Brinkman, Petra Hissink Muller, Ellen Schatorje, Esther Hoppenreijs, Annet van Royen‐Kerkhof, Sebastiaan Vastert, Berent Prakken, Erika Van Nieuwenhove, Joost Swart, Marc Jansen, Nico Wulffraat, Elizabeth Legger, Wineke Armbrust, Joseph Cafazzo, Maarten IJzerman, Alexander Mosoiu, Amy Xu, Arthur Cheng, Bruno Pereira, Trang Duong, Harper Cheng, Brenleigh Jebb, Gillian R. Currie, Rodrigo Dal Ben, Ravneet Sran, Elodie Boudes, Michelle Kip, Sytze de Rook, Regina de Geus +105 morewiley +1 more sourceWork Productivity Loss and Activity Impairment in Parents of Children With Juvenile Idiopathic Arthritis
ACR Open Rheumatology, Volume 8, Issue 10, October 2026.Objective
To determine the impact of juvenile idiopathic arthritis (JIA) on work productivity loss and daily activities of parents. Methods
The multicenter Canada‐Netherlands Understanding Childhood Arthritis Network (UCAN) CAN‐DU and CURE study captures consecutive clinical and patient‐reported data for patients and parents since 2019.Deborah A. Marshall, Rodrigo Dal Ben, Gillian R. Currie, Rae S. M. Yeung, Sebastiaan J. Vastert, Nico Wulffraat, Joost F. Swart, Susanne Benseler, on behalf of the UCAN CAN‐DU and UCAN CURE Consortia, Rae Yeung, Shirley Tse, Deborah Levy, Ronald Laxer, Brian Feldman, Elizaveta Limenis, Ruud Verstegen, Lynn Spiegel, Rayfel Schneider, Evelyn Rozenblyum, Jennifer Ji Young Lee, Alisa Rachlis, Susanne Benseler, Nicole Johnson, Muhammed Dhalla, Paivi Miettunen, Heinrike Schmeling, Marinka Twilt, Rebeka Stevenson, Deborah Marshall, Andrea Human, David Cabral, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Tommy Gerschman, Herman Tam, Mercedes Chan, Ross Petty, Roman Jurencak, Nadia Luca, Ciarán Duffy, Tala El Tal, Roberta Berard, Jonathan Park, Erkan Demirkaya, Lily Lim, Adam Huber, Bianca Lang, Elizabeth Stringer, Chelsea DeCoste, Suzanne Ramsey, Dax G. Rumsey, Daniah Basodan, Lillian Lim, Hon Yan Ng, Jeanine McColl, Tara McGrath, Michelle Batthish, Tania Cellucci, Liane Heale, Claire LeBlanc, Gaëlle Chédeville, Rosie Scuccimarri, Sarah Campillo, Piya Lahiry, Paul Dancey, Nickolas Blanchette, Alan Rosenberg, Mehul Jariwala, Tristan Kerr, Kate Neufeld, Clare Hutchinson, Gordon Soon, Dieneke Schonenberg, Mariken Gruppen, Merlijn van den Berg, Giske Biesbroek, Philomine van Pelt, Marleen Verkaaik, Sylvia Kamphuis, Danielle Brinkman, Petra Hissink Muller, Ellen Schatorje, Esther Hoppenreijs, Annet van Royen‐Kerkhof, Sebastiaan Vastert, Berent Prakken, Erika Van Nieuwenhove, Joost Swart, Marc Jansen, Nico Wulffraat, Elizabeth Legger, Wineke Armbrust, Joseph Cafazzo, Maarten IJzerman, Alexander Mosoiu, Amy Xu, Arthur Cheng, Bruno Pereira, Trang Duong, Harper Cheng, Brenleigh Jebb, Gillian R. Currie, Rodrigo Dal Ben, Ravneet Sran, Elodie Boudes, Michelle Kip, Sytze de Rook, Regina de Geus +109 morewiley +1 more sourceBiologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2036-2049, October 2026.Objective
Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka +30 morewiley +1 more sourceAssociation of Clonal Hematopoiesis With Incident, Late‐Onset, Seropositive Rheumatoid Arthritis
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2063-2073, October 2026.Objective
Clonal hematopoiesis (CH), defined by acquired driver mutations in hematopoietic stem cells, is associated with many inflammatory diseases of aging. We investigated whether CH and its subtypes, CH of indeterminate potential (CHIP) and mosaic chromosomal alteration (mCA), are associated with incident rheumatoid arthritis (RA) and whether ...Kun Zhao, Yash Pershad, J. Brett Heimlich, Michelle Ormseth, C. Michael Stein, Brian Sharber, Caitlyn Vlasschaert, Alexander G. Bick, Robert W. Corty +8 morewiley +1 more sourceA Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2149-2159, October 2026.Objective
Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported.Longfang Chen, Qihua Dai, Yu Xiao, Jialin Dai, Mengyan Wang, Yuning Ma, Yujie Shen, Zhimo Xu, Jianfen Meng, Xia Chen, Da Yi, Yue Sun, Hui Shi, Honglei Liu, Xiaobing Cheng, Yutong Su, Junna Ye, Huihui Chi, Zhuochao Zhou, Tingting Liu, Jialin Teng, Chengde Yang, Jinchao Jia, Qiongyi Hu +23 morewiley +1 more sourceValidation of International Classification of Diseases Code–Based Case Definitions of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis From Administrative Health Data
Arthritis &Rheumatology, Volume 78, Issue 10, Page 2160-2170, October 2026.Objective
Immune checkpoint inhibitors (ICIs) for cancer can lead to immune‐related adverse events, including ICI‐associated inflammatory arthritis (ICI‐IA). There are no validated International Classification of Diseases (ICD) code–based case definitions for ICI‐IA.Manar Elsayed, Zoe Hsu, Finlay A. McAlister, William D. Leslie, Lisa M. Lix, Sasha Bernatsky, Suzanne N. Morin, Michelle M. Graham, Aurore Fifi‐Mah, Shahin Jamal, Janet Roberts, Carrie Ye +11 morewiley +1 more sourceGlycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein
Biotechnology and Bioengineering, Volume 123, Issue 10, Page 2605-2612, October 2026.ABSTRACT
Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for Frances Rocamora, Chen‐Lin Hsieh, Sanne Schoffelen, Johnny Arnsdorf, Eric A. Toth, Abdul S. Yunus, Thomas E. Cleveland IV, Sara Petersen Bjørn, Mina Ying Min Wu, Noel G. McElvaney, Bjørn Gunnar Rude Voldborg, Thomas R. Fuerst, Nathan E. Lewis +12 morewiley +1 more source
